

**Creo Medical Group plc**  
("Creo", the "Company" or the "Group")

**Change of Nominated Adviser**

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that following the acquisition of Numis Securities Limited's parent company by Deutsche Bank AG on 23 October 2023 and its ongoing integration, its Nominated Adviser and Broker has changed from Numis Securities Limited to Deutsche Bank AG, London Branch with immediate effect.

**For further information please contact:**

**Creo Medical Group plc**

Richard Craven, Company Secretary

[www.creomedical.com](http://www.creomedical.com)

Via Walbrook PR

**Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser)**

Freddie Barnfield / Duncan Monteith / Sher Shah

+44 (0)20 7260 1000

**Walbrook PR Ltd**

Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or [creo@walbrookpr.com](mailto:creo@walbrookpr.com)

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654



**About Creo Medical**

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website [www.creomedical.com](http://www.creomedical.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEDLFLEQLFBBZ